Document is current

Article History

Received: 30 July 2021

Accepted: 5 September 2021

First Online: 14 September 2021

Declarations

:

: The study was approved by the ethical committees of each participating institution, following the principles of the Declaration of Helsinki. Written informed consent was obtained from each participant.

: All the authors gave their consent to publication.

: TI received honoraria from the Organization for Clinical Medicine Promotion. AT received honoraria from Boehringer Ingelheim and research funding from GlaxoSmithKline. KD received honoraria and a scholarship from Mitsubishi Tanabe Pharma Corporation. KS received grants from Omron Health Care, Asahi Calpis Wellness, Teijin Pharma, and Fukuda Lifetech. K Kida received honorarium from Daiichi Sankyo Co., Novartis Pharmaceuticals Co., Ltd., Otsuka Pharmaceutical Co., Ltd., AstraZeneca K.K., and Ono Pharmaceutical Co., Ltd. HT received honoraria from Abbott Medical Japan, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kowa, Ono, Mitsubishi Tanabe, and Takeda. NO received honoraria from Daiichi Sankyo Co, Ltd, and Otsuka Pharmaceutical: scholarship from Daiichi Sankyo Co, Ltd, and Otsuka Pharmaceutical. MS received grants and personal fees from Mitsubishi Tanabe, Takeda, Daiichi Sankyo, Astellas, Pfizer, Novartis, Boehringer Ingelheim, Bayer, MSD, Kowa, and AstraZeneca. SU received grants from Kowa, Bristol-Myers Squibb, Bayer, honoraria from MSD, Boehringer Ingelheim, and Chugai. JO belongs to the endowed department of Fukuda Denshi. KN received research grants from Asahi Kasei, Astellas, Bayer, Boehringer Ingelheim, Mitsubishi Tanabe, Teijin, and Terumo; scholarships from Astellas, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Daiichi Sankyo Healthcare, Takeda, and Teijin; and personal fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo Healthcare, Eli Lilly, Kowa, Mitsubishi Tanabe, MSD, Novartis, Ono, Takeda, and Teijin. All other authors declare no competing interests.